Australia, a Hotbed for Regenerative Medicine
AGC Asahi Glass has entered into a strategic collaboration and license agreement with Regeneus. Regeneus is developing an allogeneic adipose-derived MSC therapy called Progenza for the treatment of osteoarthritis (OA) and has recently concluded a Phase I trial in Australia.
http://regeneus.com.au/media/news/JapanChemicalDailyArticle_June2017.pdf
